Keywords: ustekinumab, boosts, 12-week, pasi-75, scores, one-year, data
Ustekinumab boosts 12-week PASI-75 scores
Article | 11 February 2008
One-year data from the second, double-blind, placebo-controlled Phase III study PHOENIX 1 showed that ustekinumab given every 12 weeks provided sustained, clinically-meaningful ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
